Shilpa Medicare Ltd (SHILPAMED):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Shilpa Medicare Ltd (SHILPAMED) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9995
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shilpa Medicare Ltd (Shilpa Medicare) focuses on the development, manufacture and commercialization of generic pharmaceutical products and active pharmaceutical ingredients (APIs). It offers medicines for the treatment of cancer, infectious diseases such as HIV, multiple sclerosis and immunological disorders among others. The company’s cancer treatment products include anastrozole, bicalutamide, bortezomib, carboplatin and imatinibmesylate among others. Shilpa Medicare’s API products include acebrophylline, valsartan, ambroxol HCl, buflomedil HCl, nifedipine and terfenadine, among others. It exports its drug products to the US, Canada, Australia, Japan, Germany, Switzerland and the Netherlands. The company also offers contract research and manufacturing services for APIs, formulations, new drug delivery systems (NDDS) and biotech products. Shilpa Medicare is headquartered in Raichur, Karnataka, India.

Shilpa Medicare Ltd (SHILPAMED) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
TA Associates Acquires 3.7% Stake in Shilpa Medicare for USD25.4 Million 10
Merger 12
Shilpa Medicare and Navya Biologicals Plan to Merge 12
Licensing Agreements 13
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 13
Equity Offering 14
Shilpa Medicare Announces Private Placement Of Shares For US$12.4 Million 14
Acquisition 15
Shilpa Medicare Sells Shares in Raichem Medicare to Ice 15
Shilpa Medicare to Acquire Remaining 32.06% Stake in Nu Therapeutics for USD0.5 Million 16
Shilpa Medicare Ltd – Key Competitors 17
Shilpa Medicare Ltd – Key Employees 18
Shilpa Medicare Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 21
Corporate Communications 21
Oct 24, 2017: Shilpa Medicare: Resignation of Chief Financial Officer (CFO) 21
Legal and Regulatory 22
Jul 11, 2018: Shilpa Medicare: Update on Establishment Inspection Report 22
Apr 23, 2018: Shilpa Medicare Receives EU-GMP certification from AGES 23
Mar 17, 2018: Shilpa Medicare Provides Update On USFDA Inspection At Formulation Unit At Jadcherla, Telangana 24
Mar 16, 2018: Shilpa Medicare Provides Update On US FDA Inspection 25
Jan 22, 2018: Shilpa Medicare Announces Completion of US FDA Inspection At API Facilities In Raichur, Karnataka 26
Dec 05, 2017: Shilpa Medicare receives 483 observations from US FDA for SEZ Formulation Facilities 27
Oct 07, 2017: Shilpa Medicare: Intimation U/R 3O of the SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-53O549 28
Jul 31, 2017: Shilpa Medicare Provides Update On US FDA Inspection At manufacturing facility located at Jadcherla, Telangana 29
Apr 12, 2017: Shilpa Medicare Provides Update On US FDA Inspection At Manufacturing Facilities Located At Raichur 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shilpa Medicare Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TA Associates Acquires 3.7% Stake in Shilpa Medicare for USD25.4 Million 10
Shilpa Medicare and Navya Biologicals Plan to Merge 12
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 13
Shilpa Medicare Announces Private Placement Of Shares For US$12.4 Million 14
Shilpa Medicare Sells Shares in Raichem Medicare to Ice 15
Shilpa Medicare to Acquire Remaining 32.06% Stake in Nu Therapeutics for USD0.5 Million 16
Shilpa Medicare Ltd, Key Competitors 17
Shilpa Medicare Ltd, Key Employees 18
Shilpa Medicare Ltd, Other Locations 19
Shilpa Medicare Ltd, Subsidiaries 19

List of Figures
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shilpa Medicare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Shilpa Medicare Ltd (SHILPAMED):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mahagenco:企業の戦略的SWOT分析
    Mahagenco - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Monsanto Co (MON):企業の財務・戦略的SWOT分析
    Monsanto Co (MON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Eneco Holding NV-エネルギー分野:企業M&A・提携分析
    Summary Eneco Holding N.V. (Eneco) is an integrated energy company. It produces, trades, transmits and supplies gas, electricity and heat. Eneco undertakes the sale, rental, installation, and maintenance of heating and hot water equipment; and maintenance of the electricity, gas and district heat ne …
  • ID Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary ID Pharma Co Ltd (ID Pharma), formerly DNAVEC Corp is a manufacturer and commercializer of gene medicines. The company develops regenerative medicines, cell therapy and other bio products. It provides vector platforms such as Sendai virus vector in its drug development process. ID Pharma’s v …
  • Itau Unibanco Holding SA:企業の戦略・SWOT・財務情報
    Itau Unibanco Holding SA - Strategy, SWOT and Corporate Finance Report Summary Itau Unibanco Holding SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tepha Inc-医療機器分野:企業M&A・提携分析
    Summary Tepha Inc (Tepha) is a medical device company that develops and commercializes medical device components and finished goods. The company offers products such as absorbable monofilament suture, absorbable monofilament mesh, composite mesh and absorbable surgical film. It also provides platfor …
  • Lamb Weston Holdings, Inc. (LW):企業の財務・戦略的SWOT分析
    Lamb Weston Holdings, Inc. (LW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Shimadzu Corp (7701)
    Shimadzu Corp (7701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Saudi Telecom Co (7010):企業の財務・戦略的SWOT分析
    Saudi Telecom Co (7010) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Illumina, Inc.:企業の戦略・SWOT・財務情報
    Illumina, Inc. - Strategy, SWOT and Corporate Finance Report Summary Illumina, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Atlantic Power Corporation:発電所・企業SWOT分析
    Atlantic Power Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • ImmunoCellular Therapeutics Ltd (IMUC)-医療機器分野:企業M&A・提携分析
    Summary ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product …
  • DiaCarta Inc:医療機器:M&Aディール及び事業提携情報
    Summary DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection ki …
  • Ardent Health Services:企業の戦略・SWOT・財務分析
    Ardent Health Services - Strategy, SWOT and Corporate Finance Report Summary Ardent Health Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • The Boston Beer Company, Inc.:企業の戦略・SWOT・財務分析
    The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Oilex Ltd (OEX):企業の財務・戦略的SWOT分析
    Summary Oilex Ltd (Oilex) is an oil and gas company that acquires, explores and develops petroleum resources. The company’s projects in Australia include STP-EPA-0106, STP-EPA-0131, and STP-EPA-0107. Its STP-EPA-0106 project is located in onshore north-western Australia. Oilex’s Indian projects are …
  • Biodesix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biodesix Inc (Biodesix) is a molecular diagnostics company which discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests in oncology for patients and doctors to enable precision medicine. These tests are used for early detection of diseases, diagnosis a …
  • Gleason Research Associates Inc:企業の戦略的SWOT分析
    Gleason Research Associates Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Ming Fai International Holdings Limited:企業の戦略・SWOT・財務情報
    Ming Fai International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Ming Fai International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Orphazyme AS (ORPHA):製薬・医療:M&Aディール及び事業提携情報
    Summary Orphazyme A/S (Orphazyme) formerly Orphazyme ApS, is a biopharmaceutical company that develops heat shock protein based therapies for the treatment of orphan protein-misfolding diseases. Its lead product drug candidate arimoclomol is under clinical development for treating neuromuscular dise …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆